18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions

Study Overview
=================
Brief Summary
-----------------
Background: 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) can identify well low and high grade brain tumors. However, increased FDOPA uptake has been reported in non-tumoral brain lesions. The aim was to analyse FDOPA-PET in patients with non-tumoral brain lesions and to compare them with patients with (low and high grade) brain tumors. Methods: retrospective analyse. Patients consecutively recruited with suspected primary brain tumor (based on clinical and MRI findings) referred for FDOPA-PET at Nimes university Hospital between June 2015 and June 2019. FDOPA-PET parameters (maximum and mean lesion standardized uptake values [SUV] and ratios comparing lesion with different background uptake SUV) and thresholds were analysed in search for those offering optimal discrimination between non-tumoral and tumoral lesions.

Official Title
-----------------
18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions

Conditions
-----------------
Brain Tumor

Intervention / Treatment
-----------------
* Diagnostic Test: FDOPA-TEP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of defined tumor (histology was required) or non-tumor (diagnosed by histological or other analyses) diagnosis, clinical and MRI follow-up of >24 months, FDOPA-PET scan <2 months before surgery or stereotactic biopsy (when performed)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with tumoral brain lesion<br>The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients. | Diagnostic Test: FDOPA-TEP<br>* FDOPA-TEP performed as part of the normal management of a suspected brain tumour<br>|
| patients with non-tumoral brain lesion<br>The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection). | Diagnostic Test: FDOPA-TEP<br>* FDOPA-TEP performed as part of the normal management of a suspected brain tumour<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FDOPA-TEP | analyse of FDOPA-PET parameters (maximum and mean lesion standardized uptake values [SUV] and ratios comparing lesion with different background uptake SUV) | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tumor, tumoral, non-tumoral, pseudotumoral, 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine, FDOPA, positron emission tomography, PET